Connect with us

Companies

Facebook Removes Woman’s Account Because Her First Name is Isis

Published

on

The goddess Isis was an important figure in ancient Egypt. The ideal wife with a name meaning “throne,” she was the very embodiment of the Pharaoh’s supernatural right to power. Thus it’s no surprise that some women might see fit to name their daughters after her. In fact, Isis was one of the most popular baby names among Portuguese people in 2012.

// -- Discuss and ask questions in our community on Workplace. Don't have an account? Send Jonas Borchgrevink an email -- //

That said, Facebook’s not about to let you be a member of their exclusive, 1-billion-plus people network if you have such a first name. We’re being hyperbolic, but so it would seem. Isis Anchalee is an engineer living in San Francisco, and after the attacks in Paris last Friday, in perhaps a fat fingered move, the social media giant disabled her account.

By all accounts, Anchalee is very much not involved with the terrorist organization known by several names, chiefly the Islamic State. She is just an engineer going about her life. The move was ultimately reversed. Anachlee commented on the ridiculousness via Twitter at the time:

isis-tweet

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

This is not the first time Facebook has decided that your name is not actually your name. The company has come under fire several times over the past few years for disabling the accounts of Native Americans whose names the company discounted as not being real. One such user’s last name was called into question, that user being Shane Creepingbear.

Also read: Facebook Set to Appeal Belgian Data Privacy Decision

There is a certain arrogance in claiming to know whether or not someone else is using their real name. After all, until we are adults, names are not something we have a say over. One of the most famous Internet entrepreneurs of all time, Kim Dotcom, legally changed his name to Dotcom years ago. Does Facebook expect people born to more creative parents to change their names to suit its “real names policy”?

Hard telling, but what is clear is that the company believes users being identified by their real names is an important part of its experience. The policy is confusing in that after a user’s account is suspended, they must submit legal documents proving their identity. But earlier this year Mark Zuckerberg told BuzzFeed that it doesn’t necessarily have to be a legal name that users are signing up to Facebook with.

Real name does not mean your legal name. Your real name is whatever you go by and what your friends call you. If your friends all call you by a nickname and you want to use that name on Facebook, you should be able to do that.

Facebook cites the safety of its users as the biggest motivator for the policy, but from a business perspective, it seems obvious that knowing people’s real names is better for advertising purposes. Over the years, the Internet has evolved from a place where people were mostly pseudonymous to one where people are mostly able to be found with a few key strokes and button clicks.

Image from Shutterstock.

Important: Never invest money you can't afford to lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here.



Feedback or Requests?

2 Comments

2 Comments

  1. englishvinal

    November 19, 2015 at 10:14 pm

    Guess what?.. I have somehow managed to survive all these years (however long it is that FaceBook has been around), without EVER accessing FaceBook.. or having a FaceBook account.

    That fact has not impacted my life, or made my life any different than it was BEFORE facebook came along.

    That said…. I use e-mail, and I understand that so doing subjects me to government spying and big business spying too… (sending me advertisements for things I will NOT buy just because they are invading my space)..

    People… wake up and do your level best to CLOSE out that invasive FaceBook account…. and void out the information that you can. And go back to living life as if it didn’t exist.

    • P. H. Madore

      November 23, 2015 at 9:31 pm

      You know what’s crazy? There’s no such thing as closing one! They merely deactivate. People can be off for years, come back, and everything’s right there.

You must be logged in to post a comment Login

Leave a Reply

Artificial Intelligence

Bitcoin Giant Bitmain Enters the High Stakes AI Race

Published

on

Artificial Intelligence

The Sophon, named for a fictional proton-sized supercomputer, could be the tool to train neural networks in data centers worldwide. It is the latest project being developed by Bitmain Technologies Ltd., the bitcoin mining giant that has carved out a dominant position in bitcoin mining.

// -- Discuss and ask questions in our community on Workplace. Don't have an account? Send Jonas Borchgrevink an email -- //

Such chips, called application-specific integrated circuits (ASICs), could unleash a new wave of distributed computing, according to Michael Bedford Taylor, a University of Washington professor who studies bitcoin mining and chips.

Sophon is due to debut before the end of the year.

Bitmain Has The Know-How

Bitmain has the background to play a role in the expanding artificial intelligence industry. The company designs the silicon that goes in bitcoin mining equipment, assembles the machines and sells them worldwide, in addition to its own bitcoin mining operation and the ones that it manages for other mining pools.

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

Bitmain’s founders are not averse to playing a spoiler role.

Jihan Wu, the co-founder of Bitmain, supports the New York Agreement that seeks to double the bitcoin block size under the SegWit2X proposal, a move that some in the bitcoin community view as an attempt to give the miners control over bitcoin.

Some also believe Wu was behind the recent bitcoin split known as bitcoin cash, which at least one of Bitmain’s miners supported, a contention that Wu has denied. Wu points out that he was among the supporters of Bitcoin Unlimited, an earlier bitcoin scaling proposal that did not get activated.

Why Wu Supports Forks

Wu nonetheless said splits should be allowed. He said a fork is inevitable since people in the bitcoin community do not agree on how to best scale bitcoin.

Wu met Micree Zhan, Bitcoin’s co-founder, when Zhan was running DivaIP in 2010, a company that made a device that allowed a user to stream a TV show on a computer screen.

In 2011, Wu needed a chip designer to build a mining operation and approached Zhan. Zhan first designed an ASIC to run SHA-256, the cryptographic calculation used in bitcoin, at maximum efficiency. It took him six months to finish the job. His first rig, Antminer S1, was ready in November 2013.

Bitmain felt the sting of the 2014 Mt. Gox meltdown. But by 2015, bitcoin’s price bottomed out and later recovered. In the meantime, Bitmain introduced its Antminer S5.

Bitmain now employs 600 people in Beijing.

Also read: Bitmain clarifies its ‘bitcoin cash’ fork position

Ready To Take On Google

Bitmain has since developed a deep learning chip with improved efficiency. Users will be able to build their own models on the ASICs, enabling neural networks to deliver results at a faster pace. Google’s DeepMind unit used this technique to train its AlphaGo artificial intelligence.

Bitmain plans to sell the chips to any company looking to train its own neural nets, including firms like Alibaba, Tencent and Baidu. Bitmain could build its own data centers with thousands of deep learning rigs, renting out the computation power to clients the way it does with bitcoin mines.

Professor Taylor said companies like Bitmain that have excelled in bitcoin mining could take on the Googles and Nvidias since they have developed the skills to survive in an ultra-competitive and highly commoditized industry, and have the system level design expertise and the ability to reduce data center costs.

Important: Never invest money you can't afford to lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here.



Feedback or Requests?

Continue Reading

Business

Biotech And Industrial Metals Top Penny Stocks To Watch For August

Published

on

Leading market benchmarks hit new highs in July, generating interest in small-cap stocks and low-priced securities for August, according to the Investopedia penny stocks to watch for August.

// -- Discuss and ask questions in our community on Workplace. Don't have an account? Send Jonas Borchgrevink an email -- //

Suffering sectors like industrial metals and brick-and-mortar retailers also perked up, driving swing traders and bottom feeders into the market. Such developments bode well for penny stocks in the near-term, even though traders have to recognize higher than average risk.

Biotech stocks performed well during the month as major sector funds broke out of basing patterns set in 2015. The strength of biotechs signals the start of secular uptrends that should support rallies at all capitalization levels in the next few months.

Four of this month’s stocks return from the previous two months while the balance are newcomers.

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

1. ImmunoGen Inc. (IMGN)

Source: Investopedia

ImmunoGen, Inc. has grown by more than 70% since it joined the penny stock watch list in June, raising odds for double digit growth.

Immunogen, a provider of antibody-drug conjugates for the treatment of cancer, leads the top penny stocks for the second straight month after joining the list in June as the number four top stock to watch.

The stock posted a 12-year high at $20.25 in 2013 and sold off to $5.34 in December 2014. A recovery in 2015 stalled less than a point below the prior peak, creating a decline that continued into an 18-year low at $1.51 in November 2016.

The stock reached a 14-month high above $8.00 in early July. A mid-month pullback dropped the stock into intermediate support at the 50-day EMA, creating a healthy bounce that could now test the prior high, pushing into double digits.

ImmunoGen creates targeted cancer therapeutics. The company’s candidate, mirvetuximab soravtansine, is in a Phase 3 trial for an ovarian cancer, and is in Phase 1b/2 testing in combination regimens for an earlier-stage disease.

The technology is used in Roche’s Kadcyla, in three other clinical-stage ImmunoGen product candidates, and in programs in development by Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.

2. RADA Electronic Industries, Ltd. (RADA)

Source: Investopedia

RADA Electronic Industries, Ltd. (RADA), a defense electronics system of advanced electronic systems for airborne and land applications, rose from number 7 in July’s top penny stocks to watch to number two in August.

The stock fell into a multi-decade decline after it joined Nasdaq in the 1990s. It ground out a series of lower highs and lows through January 2016’s all-time 54-cent low. The stock spent 16 months moving sideways in a narrow basing pattern before turning higher in May 2017 and rallying back to 2016 resistance at $1.78. The bullish activity completed a cup and handle breakout pattern that could point to a fast rally into the August 2015 gap between $3.70 and $2.50.

The stock continues to gain strength, targeting the August 2015 gap at $4.24

Revenues totaled $4.7 million in the 2017 first quarter, up 91% compared to revenues of $2.5 million in the first quarter of 2016.

Gross profit totaled $1.7 million in the first 2017 quarter of 2017, a gross margin of 35.7%, compared to gross profit of $6,000 (gross margin of 0.2%) in the 2016 first quarter.

Operating income was $0.4 million in the first 2017 quarter compared to an operating loss of $1 million in the 2016 first quarter.

Net income attributable to RADA’s shareholders in the 2017 first quarter was $0.4 million, $0.02 per share, versus a net loss of $1.8 million, or $0.23 per share, in the 2016 first quarter.

3. 22nd Century Group, Inc. (XXII)

Source: Investopedia

22nd Century Group, Inc., a plant biotechnology company that is a provider of tobacco harm reduction and development of proprietary hemp/cannabis strains, rose from the number five spot in July’s top penny stocks to watch to number three in August.

The stock broke out above multi-year resistance near $1.50 in 2013, rallying to a record high a few months later at $6.36. It then began a persistent decline through August 2015 before finding support at 56 cents, followed by a bounce to $1.75.

The stock traded within those boundaries for 22-months, bouncing at support three times and reversing at resistance in equal measure. The price returned to that level a fourth time, improving odds for a breakout that could double the price in the year’s second half.

The stock found support near 70 cents in the second half of the year, testing that level three times ahead of a March 2017 uptick that has now reached ranged resistance. A breakout over $2 should draw strong buying interest favoring a high percentage rally back to its 3-year high.

The stock joined the Russell Microcap Index two months ago, when FTSE Russell reconstituted its U.S. and global equity indexes.

Membership in the Russell Microcap Index signifies automatic inclusion in the value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

22nd Century Group focuses on genetic engineering and plant breeding that allows the increase or decrease of nicotine levels in tobacco plants and cannabinoids levels in cannabis plants. Its primary goal for tobacco is to lessen the harm caused by smoking. The primary goal for cannabis is to develop proprietary hemp/cannabis strains for new medicines and agricultural crops.

4. Ballard Power Systems, Inc. (BLDP)

Source: Investopedia

Ballard Power Systems, Inc. (BLDP), a provider of clean energy products that reduce customer costs and risks, and helps customers solve challenges in their fuel cell programs, rose from the number 10 spot in the July penny stocks to watch to the number four spot in August.

The stock reached an all-time high at $144.95 in 2000 before falling for more than 12 years, reaching an all-time low at 56 cents. A 2013 uptrend continued through 2014, reaching an 8-year high at $8.38, followed by a correction that returned to 2015 resistance at $3.10.

The recovery wave reached new resistance in April 2017, generating a 3-month symmetrical triangle pattern that could yield an uptrend into the prior high.

Total revenue was $22.7 million in the last quarter, an increase of 39% from growth in both power products and technology solutions.

Gross margin was 42% in the quarter, an improvement of 22 points due to a shift in product mix toward higher margin technology solutions and a heavy duty motive for the China market, including the establishment of a production line in Yunfu, China for the manufacture and assembly of FCvelocity-9SSL fuel cell stacks.

Cash operating costs were $10 million in the quarter, a 6% increase due to higher research and product development expenditures as well as a stronger Canadian dollar relative to the U.S. dollar, since a significant amount of cost is denominated in Canadian dollars.

Low-priced biotech stocks have risen following a long slumber, with steady buying interest likely to continue. This group should offer a variety of profitable penny stock plays during the quiet summer trading season, while low-priced stocks in other sectors move into narrow trading ranges.

5. Trilogy Metals, Inc. (TMQ)

Source: Investopedia

Trilogy Metals Inc., which engages in the development and exploration of mineral properties, joins the top penny stocks to watch list this month at number 5. The Vancouver, Canada-based company went public on the U.S. exchanges in April 2012 at $3.20, beginning an immediate downtrend to an all-time low at 15 cents in January 2016. A recovery wave mounted the 200-day EMA at 60 cents that stalled three months later, yielding a narrow basing pattern into a July 2017 recovery that has reached a 2-year high at $1.22.

A pullback to new support in the 80- to 85-cent price range should mark a low-risk buying opportunity, as the upside that could reach $2.

Trilogy Metals Inc. reported a strong working capital position of $20.1 million in the second quarter, with cash on hand of $14.5 million.

For the three months ending May 31, 2017, the company reported a net loss of $2.4 million compared to a net loss of $1.6 million for the corresponding period in 2016. This variance was primarily due to the size of the field programs at the Upper Kobuk Mineral Projects in 2017 as well as the timing of the program.

An increase of $840,000 of mineral property expenses occurred during the three months ended May 31, 2017 compared to the three months ended May 31, 2016. In 2017, the field program at Arctic and Bornite began with drilling by early June compared to 2016 where the field program kicked off in early July. This earlier start resulted in an increased mineral property expense during the second quarter of 2017. Additionally, an increased level of ongoing technical studies was occurring during the three months ended May 31, 2017 compared to the corresponding period in 2016.

The company announced a financial partnership with South32 Limited for an option to form a 50/50 joint venture for a minimum investment of $150 million. South32 is required to fund a minimum of $10 million per year for up to three years to keep the option in good standing. The first $10 million has been advanced to the company and will be spent on a 12,000-meter exploration drill program at the Bornite deposit, which is already underway.

6. Antares Pharma, Inc. (ATRS)

Source: Investopedia

Antares Pharma, Inc., which focuses on self-administered parenteral pharmaceutical products, caught fire after suffering an all-time low at 29 cents in January 2009, then delivering a strong uptrend continuing into the July 2012 all-time high at $5.58. The stock then fell in multiple selling waves that ended at a 6-year low in March 2016.

The subsequent recovery has now completed a round trip into the April 2015 high, retracing half of the multi-year decline. The price has consolidated above $3 for the past three months, establishing the final stage of a 2-year cup and handle pattern targeting the multi-year high.

The company recently reported operating and financial results for the second quarter ended June 30, 2017. The company reported revenue of $13.4 million and a net loss per share of $0.02 for the three months ended June 30, 2017.

Revenue for the three months ending June 30, 2017 was $13.4 million, compared to $12.2 million for the comparable period in 2016. For the six months ended June 30, 2017, total revenue was $25.4 million, versus total revenue of $24.5 million for the six months ended June 30, 2016.

Product sales were $7.3 million for the three months ended June 30, 2017, compared to $8.7 million for the comparable period in 2016, totaling $17.4 million for the six months ended June 30, 2017 compared to $19.5 million in the same period of 2016.

The decrease for the period was primarily driven by a reduction in sales of pre-launch auto injector devices for use with Teva’s generic epinephrine product and reduced sumatriptan product shipments to Teva partially offset by increased sales of OTREXUP.

The company also completed a non-dilutive, 5-year debt financing with Hercules Capital, providing Antares the ability to draw up to $35 million, with the first tranche of $25 million funded upon execution of the agreement.

7. Corindus Vascular Robotics, Inc. (CVRS)

Source: Investopedia

Corindus Vascular Robotics, Inc. topped out near $4.60 in 2015 and began a steep decline in January 2017 when it posted a multi-year low at 40 cents. The stock rebounded on strong volume one month later, marking an uptrend that reached an 18-month high at $2.25 in early July. The stock has been consolidating at new support for the last three weeks, settling on the 50-day EMA while its on-balance volume holds near the rally high. The bullish configuration favors continuing upside that could reach 2015 resistance at $3.

Second quarter revenue was $2.3 million compared to $0.5 million for the same period in the prior year. The increase is due mainly to CorPath GRX Systems and capital upgrade sales.

The company installed three new CorPath GRX Systems in the second quarter, increasing the installed base to 16 systems and the total installed base to 51 systems. The installed base of 16 systems accounted for almost 90% of all CorPath cassettes shipped for revenue in the second quarter.

Gross profit was $58,000 for the second quarter, compared to a loss of $0.6 million for the second quarter of 2016. The cost of revenues for the second quarter continued to include the effect of under-utilization of production facilities as well as the cost of CorPath GRX system upgrades installed pursuant to contractual service arrangements with no corresponding revenue in the period.

Selling, general and administrative expenses were $5.9 million, compared to $4.4 million in the second quarter of 2016. The increase is primarily due to higher compensation and travel expenses associated with incremental sales headcount, investment in medical education and international sales initiatives, and incremental non-cash stock-based compensation expense related to the CEO and commercial leadership transitions during 2016.

8. Medical Transcription Billing Corp. (MTBC)

Source: Investopedia

Medical Transcription Billing Corp., a healthcare information technology company that provides proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings, went public at $4.28 in July 2014 and entered a downtrend that continued to the April 2017 all-time low at 29 cents. The stock recovered two sessions later in reaction to positive sales news and topped out at $3.84 in mid-May.

A subsequent pullback has now since reached support at the 200-day EMA near $1.20, with a rally from this level generating buying signals favoring ongoing upside into the second quarter high.

Revenues for second quarter 2017 were $7.8 million, an increase of 49% versus $5.2 million in the same period last year. The increase was mainly due to the MediGain acquisition.

The second quarter 2017 GAAP net loss was $1.7 million, or 22% of revenue, an improvement of $1 million compared to a net loss of $2.7 million in the first quarter 2017. The GAAP net loss in the second quarter 2017 was mostly a result of non-cash amortization and depreciation expenses of $1.5 million.

The second quarter 2017 GAAP operating loss was $1.4 million, or 18% of revenue, which represents an improvement of $1 million or 43% from the $2.4 million operating loss in the prior quarter.

As of June 30, 2017, the company had $5.8 million in cash and a working capital deficiency of approximately $4.1 million.

The company raised gross proceeds of $2.3 million from a registered direct offering of its common stock priced at the market on May 10, 2017. MTBC issued 1 million registered shares of common stock to a healthcare institutional investor at a purchase price of $2.30 per share. Concurrently in a private placement, MTBC issued warrants to purchase up to 2 million shares of its common stock, with an exercise price of $5 per share, which are exercisable through May 15, 2018, and would deliver potential gross proceeds of up to $10 million if exercised.

In addition, the company raised gross proceeds of $7.4 million from the sale of about 295,000 additional shares of its non-convertible Series A Preferred Stock on June 23, 2017.

9. Intrepid Potash, Inc. (IPI)

Source: Investopedia

Intrepid Potash, Inc., the only U.S. producer of muriate of potash, sold off to 2008 support at $13.80 in 2014. Two years later, the stock began a decline that reached an all-time low at 65 cents in March 2016. The stock rose above $1.50 in June before settling in a sideways pattern ahead of a December 2016 breakout that soon stalled at $3.04.

The stock spent the last eight months consolidating its gains and is now testing the rally high. A breakout could generate an uptrend reaching 200-week EMA resistance between $6 and $8.

Intrepid generated a second quarter net loss of $5.9 million, or $0.05 per share, delivering a first half net loss of $19.6 million, or $0.19 per share. This marked an improvement over the net losses of $13.4 million, or $0.18 per share, and $31.8 million or $0.42 per share, in the second quarter and the first half of 2016, respectively.
Improvements in year-over-year net loss per share were driven in part by a gain in outstanding shares from a March 2017 secondary offering.

Consolidated gross margin advanced to $3.7 million and $0.8 million in the second quarter and the first half of 2017, respectively, against the prior year. Improvements were due to lower cost solar potash production and higher average net realized potash pricing that offset lower average net realized sales prices for the product, Trio.

Cash provided by operating activities rose year-over-year to $9.7 million and $11.5 million for the second quarter and the first half of 2017, respectively. Increased cash flow was due to strong spring demand, increased potash prices, and the elimination of costlier conventionally mined potash from the production profile.

10. Tantech Holdings, Ltd. (TANH)

Source: Investopedia

Tantech Holdings, Ltd., a manufacturer bamboo-based charcoal products for industrial energy applications and household cooking, heating, purification, agricultural and cleaning uses, went public at $6.00 in March 2015 and began an uptrend that topped out at $33.97 five months later. In the next three months, the stock relinquished more than 90% of its value. Bears maintained control into the April 2017 all-time low at $1, followed by a recovery that reached a 10-month high in July.

Pricing has tested resistance at the September 2016 breakdown through the October 2015 low, with a buying surge setting the stage for upside in the $6 range.

For the six months ended December 31, 2016, revenues were $24.88 million and net earnings were $2.77 million, according to a June 2017 financial report.

Gross margins widened from 25.02% to 30.33% compared to the same period last year, with EBITDA operating margins 18.28% compared to 18.64% the prior year. Year-on-year change in operating cash flow was 32.02%, about the same as the change in earnings.

Penny stocks require investors to make some guesses about the future. Very few such stocks have a sufficient track record to indicate they will prosper. At the same time, the stocks on this list are in significant industries and have the potential to be vital players in those industries.

Important: Never invest money you can't afford to lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here.



Feedback or Requests?

Continue Reading

Biotech

Biotech Dominates July Penny Stock Picks

Published

on

July brings new opportunities to trade penny stocks, according to the Investopedia top 10 penny stocks to watch. Biotechnology stocks in particular are poised for a breakout. Biotechnology funds broke out of the long-term basing pattern in June, forcing rotational buying pressure, which bodes well for the low-priced sub-sector, with many penny stocks ready to hit multi-year highs.

// -- Discuss and ask questions in our community on Workplace. Don't have an account? Send Jonas Borchgrevink an email -- //

At the same time, the tech sector is getting sold with equal force in a profit-taking exercise that could deliver a period of under-performance for the sector’s lower-priced issues.

June’s biotechnology picks drew strong buying interest, led by ImmunoGen, Inc.’s 48% advance to a 52-week high. Small China stocks also posted strength, as China Commercial Credit, Inc. gained close to 35%. China Commercial Credit and June’s three biotech picks return to the July top penny stock list, joined by six new penny stocks.

1. ImmunoGen Inc. (IMGN)

Source: Investopedia

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

ImmunoGen, a provider of antibody-drug conjugates (ADCs) for the treatment of cancer, jumped from number four in June to the top spot in July.

The stock posted a 12-year high at $20.25 in 2013 and sold off to $5.34 in December 2014. A recovery in 2015 stalled less than a point below the prior peak, creating a decline that continued into an 18-year low at $1.51 in November 2016.

Buyers took over in 2017, generating an uptick that reversed at the 2014 resistance approximately three weeks ago. In June, the stock broke out and made the top 10 list for the first time. It could end up in the $8.00 to $10.00 price zone.

ImmunoGen creates targeted cancer therapeutics using its proprietary ADC technology. The company’s candidate, mirvetuximab soravtansine, is in a Phase 3 trial for an ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease.

The technology is used in Roche’s Kadcyla, in three other clinical-stage ImmunoGen product candidates, and in programs in development by Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.

2. China Commercial Credit, Inc. (CCCR)

Source: Investopedia

China Commercial Credit Inc. (CCCR), which provides business loans and loan guarantee services to small-to-medium enterprises (SMEs), farmers and individuals in China’s Jiangsu Province, jumped from number five in June to second place in July.

The company went public on the U.S. exchanges at $6.50 in August 2013.

The stock experienced a downtrend that bottomed out at 25 cents in February 2016 and began an upward trend that stalled at $3.20 in September. The stock hit a higher low in March 2017 before recovering, testing the 2016 high. A breakout should bring broad buying interest that could support a continued upside that could double the price by year’s end.

The company was founded in 2008 and provides business loans and loan guarantee services to small-to-medium enterprises, farmers and individuals in China’s Jiangsu Province.

3. CymaBay Therapeutics, Inc. (CBAY)

Source: Investopedia

CymaBay Therapeutics Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases, returns from the June list, where it ranked number 9. The stock rallied to an all-time high at $13.78 in February 2015, then suffered a steep downtrend that continued into the first quarter of 2016. The stock then dropped to an all-time low at 82 cents before bouncing to $3.04 in April, a yearly high, ahead of a pullback that continued into the November low at $1.15.

The stock broke above the 2016 high in February 2017, reaching a two-year high at $4.81.

Net loss for the 2017 first quarter was $5.4 million, or ($0.20) per diluted share, compared to $6.8 million, or ($0.29) per diluted share in the first quarter of 2016. Net loss in the 2017 first quarter was $1.4 million lower compared to the prior year period, primarily due to the recognition of collaboration revenue in 2017.

The rally has now reached a two-year high, attracting buying interest that could move into double digits.

4. Peiris Pharmaceuticals, Inc. (PIRS)

Source: Investopedia

Pieris Pharmaceuticals Inc., a, clinical-stage biotechnology company committed to providing solutions for oncology, respiratory disease and other therapeutic areas, moved from June’s 7th spot to July’s 4th spot. The stock launched on the OTC market in 2014, trading between $2.00 and $4.25 before falling to $1.26 in January 2016. It ground sideways through November, then tested the first-quarter low ahead of a January 2017 breakaway gap that has drawn steady buying interest. The rally gathered momentum in early May after announcing a partnership with AstraZeneca PLC and is currently testing the 2015 high, the all-time high.

The company’s product includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma as well as a half-life-optimized Anticalin protein to treat anemia. Anticalin proteins, proprietary to Pieris, are a class of therapeutics validated in the clinic and partnerships with pharmaceutical companies. Anticalin is a registered trademark of Pieris.

5. 22nd Century Group, Inc. (XXII)

Source: Investopedia

22nd Century Group, Inc. (XXII), a plant biotechnology company that is a provider of tobacco harm reduction and development of proprietary hemp/cannabis strains, broke out above multi-year resistance near $1.50 in 2013, rallying to a record high a few months later at $6.36. The stock then began a persistent decline through August 2015 before finding support at 56 cents, followed by a bounce to $1.75.

The stock has traded within those boundaries for 22-months, bouncing at support three times and reversing at resistance in equal measure. The price returned to that level a fourth time, improving odds for a breakout that could double the price in the year’s second half.

22nd Century Group is a plant biotechnology company focused on genetic engineering and plant breeding that allows the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants. The company’s main goal in tobacco is to reduce the harm caused by smoking. The main goal in cannabis is to develop proprietary hemp/cannabis strains for new medicines and agricultural crops.

The stock last month joined the Russell Microcap Index, when FTSE Russell reconstituted its U.S. and global equity indexes. Membership in the Russell Microcap Index means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

6. Corindus Vascular Robotics, Inc. (CVRS)

Source: Investopedia

Corindus Vascular Robotics, Inc. (CVRS), a developer of precision vascular robotics, returned to the national market in 2015 following a trading halt, topping out around $4.50 and starting a decline that continued to reach new lows in January 2017 when it bottomed at around 40 cents. Since that time, the price activity has been constructive, with high volume rally bursts moving the stock into 2016 resistance at $1.75. The bullish behavior has created a cup and handle basing pattern that points to an uptrend into the 2015 high following a breakout.

Revenue for the first quarter of 2017 was $0.8 million compared to $1.1 million for the same period in the prior year. The decrease is due mainly to the deferral of system revenue associated with a future obligation to upgrade multiple customer units from the company’s CorPath 200 System to the CorPath GRX System.

The company installed three new CorPath Systems in the first quarter of 2017, increasing its total installed base to 48 CorPath Systems.

Gross loss was $1.1 million for the 2017 first quarter, compared to a gross profit of $0.03 million for the 2016 first quarter. The cost of revenues for the first 2017 quarter continued to include the effect of under-utilization of production facilities and the cost of CorPath GRX System upgrades that installed pursuant to pre-existing contractual arrangements.

The company continues to expect the full year 2017 revenue to be in the range of $13.

7. RADA Electronic Industries, Ltd. (RADA)

Source: Investopedia

RADA Electronic Industries, Ltd. (RADA), a defense electronics system of advanced electronic systems for airborne and land applications, fell into a multi-decade decline after it joined the Nasdaq in the 1990s. The stock ground out a series of lower highs and lows through January 2016’s all-time 54-cent low.

The stock spent 16 months moving sideways in a narrow basing pattern before turning higher in May 2017 and rallying back to 2016 resistance at $1.78. The bullish activity completed a cup and handle breakout pattern that could point to a fast rally into the August 2015 gap between $3.70 and $2.50.

Revenues totaled $4.7 million in the 2017 first quarter, up 91% compared to revenues of $2.5 million in the first quarter of 2016.

Gross profit totaled $1.7 million in the first 2017 quarter of 2017, a gross margin of 35.7%, compared to gross profit of $6,000 (gross margin of 0.2%) in the 2016 first quarter.

Operating income was $0.4 million in the first 2017 quarter compared to an operating loss of $1 million in the 2016 first quarter.

Net income attributable to RADA’s shareholders in the 2017 first quarter was $0.4 million, $0.02 per share, versus a net loss of $1.8 million, or $0.23 per share, in the 2016 first quarter.

8. ChromaDex, Corp. (CDXC)

Source: Investopedia

ChromaDex, Corp. (CDXC), a provider of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition and pharmaceutical products, went public in April 2016 at $4.70. The stock rallied to an all-time high at $6.18 in May, then fell one month later to $2.46 in a single session, eventually posting a lower December low. It tested that support level in April 2017, then turned sharply higher, now testing 2017 resistance at $3.80. A breakout could point to a significant upside, taking the stock back to last year’s high.

For the first quarter of 2017, ChromaDex reported net sales of $4.4 million, a decrease of 39% compared to the same period of 2016, due mainly to decreased sales in its ingredients business segment, as a result of dropping its largest customer for fiscal year 2016. The ingredients segment created net sales of $2.1 million for Q1 2017, a decline of 55%, compared to the same 2016 period.

The net loss attributable to common stock holders for Q1 2017 was $1.9 million or ($0.05) per share versus a net income of $0.3 million or $0.01 per share for Q1 2016.

In May, the company announced the closing of the $16.4 million second tranche of the strategic investment of up to $25 million led by Hong Kong business leader Li Ka-shing.

Li Ka-shing has invested in many innovative companies in the last decade, including Facebook, Spotify, DeepMind, Siri, Impossible Foods and Modern Meadow. The new investment will support future ChromaDex developments in the global marketplace.

The $16.4 million second tranche follows an initial $3.5 million tranche that closed on April 27, 2017.

9. Safe Bulkers, Inc. (SB)

Source: Investopedia

Safe Bulkers, Inc. (SB), a player in the hot and cold dry bulk shipping sector, topped out at $11.48 in March 2014, then entered a downtrend reaching an all-time low at 30 cents in January 2016. A recovery wave in November stalled at $2.38, followed by sideways action that has completed a small-scale cup and handle breakout pattern. A buying spike over $2.60 can be expected to set the upside into action, supporting a rally that could surpass $5.00.

The company declared a cash dividend of $0.50 per share on its 8.00% Series B, Series C and Series D Cumulative Redeemable Perpetual Preferred Shares for the period from April 30, 2017 to July 29, 2017.

This is the 16th consecutive cash dividend declared on the company’s Series B Preferred Shares, the 13th cash dividend declared on its Series C Preferred Shares and the 12th cash dividend declared on its Series D Preferred Shares since their respective commencement of trading on the New York Stock Exchange.

10. Ballard Power Systems, Inc. (BLDP)

Source: Investopedia

Ballard Power Systems, Inc. (BLDP) is a provider of clean energy products that reduce customer costs and risks, and helps customers solve challenges in their fuel cell programs. The stock reached an all-time high at $144.95 in 2000 before falling into a downtrend lasting more than 12 years, sending the stock to an all-time low at 56 cents. A 2013 upward trend continued through 2014, hitting an 8-year high at $8.38, followed by a correction that’s now returned to 2015 resistance at $3.10. A breakout could catch fire, pushing the stock to a test of its 2014 high.

Total revenue was $22.7 million in the quarter, an increase of 39% from growth in both power products and technology solutions.

Gross margin was 42% in the quarter, an improvement of 22 points due to a shift in product mix toward higher margin technology solutions and heavy duty motive for the China market, including the establishment of a production line in Yunfu, China for the manufacture and assembly of FCvelocity-9SSL fuel cell stacks.

Cash operating costs were $10 million in the quarter, a 6% increase due to higher research and product development expenditures as well as a stronger Canadian dollar relative to the U.S. dollar, since a significant amount of cost is denominated in Canadian dollars.

Low-priced biotech stocks have risen following a long slumber, with steady buying interest likely to continue. This group should offer a variety of profitable penny stock plays during the quiet summer trading season, while low-priced stocks in other sectors move into narrow trading ranges.

Featured image from Shutterstock.

Important: Never invest money you can't afford to lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here.



Feedback or Requests?

Continue Reading

Trending